Giulia Gallerani

@irst.emr.it

Biosciences Laboratory
Istituto Scientifico Romagnolo per lo Studio e la Cura

Giulia Gallerani


                     Download Compact PDF  
https://researchid.co/giulia.gallerani

EDUCATION

April 2016 PhD in Medical Sciences Speciality, with scholarship granted by MIUR (young found) Alma Mater Studiorum University of Bologna.

March 2012 Master's thesis with Prof. Dott. Davide Ferrari (University of Ferrara) at the faculty of Mathematical, Physical and Natural Sciences, University of Ferrara, Italy. Title 'DEPArray: a new approach for the study of circulating tumor cells'. Secondary Supervisors: Dr. Francesco Fabbri and Dr. Wainer Zoli (Irccs IRST, Meldola, Italy). Final grade: 110/110 CUM LAUDE.

October 2008 Undergraduate degree in Biology, course of study Molecular Biology, at the faculty of Methamatical, Physical and Natural Sciences, University of Ferrara, Italy. Final year research project in molecular and cellular biology under the supervision of Prof. Dr. Paolo Pinton. Final grade: 104/110.

RESEARCH INTERESTS

I work in the circulating tumor cells research (CTC) group of the IRCCS-IRST biosciences laboratory. Our group pursues investigations of tumor cells that invade the circulatory system representing a potential cause of metastasis. In particular, my researches focus on CTCs in metastatic and non-metastatic oesophageal cancer. We study oesophageal CTCs phenotipically using the DEPArray system, a lab-on-a-chip based technology. On isolated single CTCs we perform next generation single cell analysis to study circulating tumor cells heterogeneity.
I was one of the creators of the scientific-crowdfunding campaign "TRACe" whose purpose was to raise funds for research on circulating tumor cells. TRACe was the first italian crodfunding campaign from a research institute for oncology research.
I have also gained experience FACS Canto flow cytometer (BD) for both Immunophenotyping and apoptotic assay, cell culture techniques for both the adherent and in-suspension.
27

Scopus Publications

1118

Scholar Citations

14

Scholar h-index

16

Scholar i10-index

Scopus Publications

  • Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity
    Tania Rossi, Sara Bandini, Michele Zanoni, Michela Cortesi, Michela Palleschi, et al.
    Experimental Hematology and Oncology, 2025
    The study of circulating tumor cells (CTCs) provides critical insights into the biological mechanisms underlying metastasis. This study aims to demonstrate the applicability of an integrated DEPArray-based phenotypic analysis combined with transcriptomic characterization to investigate the biology of CTCs isolated from 10 patients with metastatic breast cancer (MBC). The transcriptional profiles of CTCs were consistent with both the cancer type and epithelial characteristics. Gene set enrichment analysis identified pathways associated with synapse organization and calcium channel activity. Furthermore, distinct gene expression profiles were linked to specific metastatic sites, particularly bone metastases. We also report a rare and understudied population of CTCs, characterized by the co-expression of epithelial and leukocyte markers, observed exclusively in patient-derived samples and not in blood samples from healthy volunteers spiked with SKBR-3 and MCF-7 cell lines. This suggests that these double-positive CTCs (dpCTCs) may have a specific role in the metastatic process. The transcriptomic characterization of these rare CTCs enhances our understanding of their biology and potential involvement in metastasis. As a pilot study, our findings underscore the potential of CTC-based transcriptomics as a valuable tool for advancing clinical and biological understanding of MBC, particularly regarding metastatic mechanisms and organotropism. Moreover, it provides preliminary insights into dpCTCs, a poorly characterized population that may play a pivotal role in metastasis but remains largely unexplored. These findings could pave the way for developing targeted therapies aimed at the pathways driving metastasis and for improving patient monitoring through CTC profiling.
  • Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation
    Tania Rossi, Martina Valgiusti, Maurizio Puccetti, Giacomo Miserocchi, Michele Zanoni, et al.
    Cell Death and Disease, 2025
    Tumor dissemination is a key event in tumor progression. During this event, a main role is played by circulating tumor cells (CTCs), immune cells, and their interaction. How the immune system supports the survival and proliferation of CTCs is not fully elucidated. In this study we established an in-vitro co-culture system consisting of immune cells and CTCs from the same patient, which increased the success rate in the establishment of CTC-derived long-term cell cultures. In this system, we characterized the immune cells of successful co-cultures and the signals they exchange with cancer cells, including cytokines and extracellular vesicle (EV) content. Using this protocol, we stabilized four CTC-derived cell lines from patients with metastatic gastroesophageal cancer, which were cultured for over a year and characterized from a genetic and molecular point of view. The four cell lines harbor shared chromosomal aberrations including the amplification at 8q24.21 containing MYC and deletion 9p21.3 containing CDKN2A/B and the IFN type I cluster. The transcriptomic profile of CTC cell lines is distinct from primary tumors, and we detected the activation of E2F, G2M and MYC pathways and the downregulation of interferon response pathway. Each cell line shows a degree of invasiveness in zebrafish in-vivo, and the most invasive ones share the same mutation in RAB14 gene. In addition, the four cell lines secrete cell-line specific EVs containing microRNAs that target YAP, BRG1-AKT1, TCF8-HDAC pathways. Overall, we highlight how the immune system plays a key role in the proliferation of CTCs through EV signaling, and how CTC cell line genomic and transcriptomic alterations make these cells less visible from the immune system and likely responsible for the survival advantage in sites distant from the microenvironment of origin.
  • Vaccine-Based Immunotherapy for Oropharyngeal and Nasopharyngeal Cancers
    Daria Maria Filippini, Elisabetta Broseghini, Carlotta Liberale, Giulia Gallerani, Giambattista Siepe, et al.
    Journal of Clinical Medicine, 2025
    Viral infections such as human papillomavirus (HPV) and Epstein–Barr virus (EBV) play a critical role in the onset of oropharyngeal (OPC) and nasopharyngeal cancer (NPC), respectively. Despite advancements in targeted therapies and immunotherapies, in the recurrent/metastatic setting, these tumors remain incurable diseases with poor prognosis. The development of therapeutic tumor vaccines, utilizing either neoantigens or oncoviral antigens, represents a promising addition to the cancer immunotherapy arsenal. Research on vaccine-based immunotherapy for OPC and NPC focuses on targeting viral antigens, particularly HPV E6/E7 and EBV EBNA1/LMP2. The potential for vaccine platforms, including peptide-based, DNA, RNA, and viral vector-based vaccines, to induce durable immune responses against viral antigens is reported. The early-phase clinical trials evaluating vaccine-based therapies for HPV-related OPC and EBV-related NPC revealed safety and preliminary signs of efficacy; however, further clinical trials are crucial for validation. This review provides an overview of the current landscape of vaccine-based strategies for HPV-related OPC and EBV-related NPC, discussing their biological mechanisms and immune processes involved in anti-HPV and anti-EBV vaccine treatments, with a particular focus on the immune factors that influence these therapies.
  • Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
    Andrea Cavazzoni, Irene Salamon, Claudia Fumarola, Giulia Gallerani, Noemi Laprovitera, et al.
    Molecular Therapy, 2024
  • Settling the uncertainty about unconventional circulating tumor cells: Epithelial-to-mesenchymal transition, cell fusion and trogocytosis
    Giulia Gallerani, Tania Rossi, Manuela Ferracin, Massimiliano Bonafè
    International Review of Cell and Molecular Biology, 2023
  • ARID1A in cancer: Friend or foe?
    Beatrice Fontana, Giulia Gallerani, Irene Salamon, Ilaria Pace, Roberta Roncarati, et al.
    Frontiers in Oncology, 2023
    ARID1A belongs to a class of chromatin regulatory proteins that function by maintaining accessibility at most promoters and enhancers, thereby regulating gene expression. The high frequency of ARID1A alterations in human cancers has highlighted its significance in tumorigenesis. The precise role of ARID1A in cancer is highly variable since ARID1A alterations can have a tumor suppressive or oncogenic role, depending on the tumor type and context. ARID1A is mutated in about 10% of all tumor types including endometrial, bladder, gastric, liver, biliopancreatic cancer, some ovarian cancer subtypes, and the extremely aggressive cancers of unknown primary. Its loss is generally associated with disease progression more often than onset. In some cancers, ARID1A loss is associated with worse prognostic features, thus supporting a major tumor suppressive role. However, some exceptions have been reported. Thus, the association of ARID1A genetic alterations with patient prognosis is controversial. However, ARID1A loss of function is considered conducive for the use of inhibitory drugs which are based on synthetic lethality mechanisms. In this review we summarize the current knowledge on the role of ARID1A as tumor suppressor or oncogene in different tumor types and discuss the strategies for treating ARID1A mutated cancers.
  • From phenotypical investigation to RNA-sequencing for gene expression analysis: A workflow for single and pooled rare cells
    Tania Rossi, Davide Angeli, Giovanni Martinelli, Francesco Fabbri, Giulia Gallerani
    Frontiers in Genetics, 2022
    Combining phenotypical and molecular characterization of rare cells is challenging due to their scarcity and difficult handling. In oncology, circulating tumor cells (CTCs) are considered among the most important rare cell populations. Their phenotypic and molecular characterization is necessary to define the molecular mechanisms underlying their metastatic potential. Several approaches that require cell fixation make difficult downstream molecular investigations on RNA. Conversely, the DEPArray technology allows phenotypic analysis and handling of both fixed and unfixed cells, enabling a wider range of applications. Here, we describe an experimental workflow that allows the transcriptomic investigation of single and pooled OE33 cells undergone to DEPArray analysis and recovery. In addition, cells were tested at different conditions (unfixed, CellSearch fixative (CSF)- and ethanol (EtOH)-fixed cells). In a forward-looking perspective, this workflow will pave the way for novel strategies to characterize gene expression profiles of rare cells, both single-cell and low-resolution input.
  • Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis
    Tania Rossi, Davide Angeli, Michela Tebaldi, Pietro Fici, Elisabetta Rossi, et al.
    Cancers, 2022
    Circulating tumor cells’ (CTCs) heterogeneity contributes to counteract their introduction in clinical practice. Through single-cell sequencing we aim at exploring CTC heterogeneity in metastatic breast cancer (MBC) patients. Single CTCs were isolated using DEPArray NxT. After whole genome amplification, libraries were prepared for copy number aberration (CNA) and single nucleotide variant (SNV) analysis and sequenced using Ion GeneStudio S5 and Illumina MiSeq, respectively. CTCs demonstrate distinctive mutational signatures but retain molecular traces of their common origin. CNA profiling identifies frequent aberrations involving critical genes in pathogenesis: gains of 1q (CCND1) and 11q (WNT3A), loss of 22q (CHEK2). The longitudinal single-CTC analysis allows tracking of clonal selection and the emergence of resistance-associated aberrations, such as gain of a region in 12q (CDK4). A group composed of CTCs from different patients sharing common traits emerges. Further analyses identify losses of 15q and enrichment of terms associated with pseudopodium formation as frequent and exclusive events. CTCs from MBC patients are heterogeneous, especially concerning their mutational status. The single-cell analysis allows the identification of aberrations associated with resistance, and is a candidate tool to better address treatment strategy. The translational significance of the group populated by similar CTCs should be elucidated.
  • Case Report: Analysis of Plasma Extracellular Vesicles in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient
    Ivan Vannini, Milena Urbini, Mattia Melloni, Tania Rossi, Giulia Gallerani, et al.
    Frontiers in Medicine, 2022
    Metaplastic breast cancer (MpBC) is a rare tumor representing 1% of all breast malignancies. The prognosis of this histologic subtype is actually poor and there are no current clear-cut therapeutic guidelines. Hence, despite its uniqueness, its aggressive prognostic profile strongly encourages further studies to identify new markers and therapeutic targets. Herein, we report a case of 32-years-old patient affected with of triple negative spindle-shaped MpBC. The research of molecular targets on the primary tumor did not allow performing an effective therapeutic choice. Extracellular Vesicles (EVs) are under intense study as new potential pathophysiological markers and targets for therapeutic applications, in different tumors for their role in tumor onset, progression and aggressiveness. Here, we examined the involvement of EVs in this case, to look into the MpBC microenvironment willing to identify new potential molecular targets, pathways of aggressiveness, and markers of prognosis and therapeutic efficacy. Firstly, we characterized MpBC patient EV dimensions and surface proteins. Moreover, we analyzed the EV RNA cargo supposed to be delivered to nearby and distant recipient cells. Interestingly, we observed a dysregulation EV-contained miRNAs, which could determine an increased expression of oncogenes in the tumor microenvironment, probably enabling cancer progression. These data suggest that the characterization of miRNA cargo of EVs could be important for the identification of new markers and for the application of future new target therapies.
  • Cna profiling of single ctcs in locally advanced esophageal cancer patients during therapy highlights unexplored molecular pathways
    Giulia Gallerani, Tania Rossi, Martina Valgiusti, Davide Angeli, Pietro Fici, et al.
    Cancers, 2021
    Background: Here, we monitored the evolution of CTCs spread in 11 patients affected by locally advanced EC who were undergoing therapy. Methods: In this perspective study, we designed multiple blood biopsies from individual patients: before and after neoadjuvant chemo-radio therapy and after surgery. We developed a multi-target array, named Grab-all assay, to estimate CTCs for their epithelial (EpCAM/E-Cadherin/Cytokeratins) and mesenchymal/stem (N-Cadherin/CD44v6/ABCG2) phenotypes. Identified CTCs were isolated as single cells by DEPArray, subjected to whole genome amplification, and copy number aberration (CNA) profiles were determined. Through bioinformatic analysis, we assessed the genomic imbalance of single CTCs, investigated specific focal copy number changes previously reported in EC and aberrant pathways using enrichment analysis. Results: Longitudinal monitoring allowed the identification of CTCs in at least one time-point per patient. Through single cell CNA analysis, we revealed that CTCs showed significantly dynamic genomic imbalance during treatment. Individual CTCs from relapsed patients displayed a higher degree of genomic imbalance relative to disease-free patients’ groups. Genomic aberrations previously reported in EC occurred mostly in post-neoadjuvant therapy CTCs. In-depth analysis showed that networks enrichment in all time-point CTCs were inherent to innate immune system. Transcription/gene regulation, post-transcriptional and epigenetic modifications were uniquely affected in CTCs of relapsed patients. Conclusions: Our data add clues to the comprehension of the role of CTCs in EC aggressiveness: chromosomal aberrations on genes related to innate immune system behave as relevant to the onset of CTC-status, whilst pathways of transcription/gene regulation, post-transcriptional and epigenetic modifications seem linked to patients’ outcome.
  • Early Detection and Investigation of Extracellular Vesicles Biomarkers in Breast Cancer
    Erika Bandini, Tania Rossi, Emanuela Scarpi, Giulia Gallerani, Ivan Vannini, et al.
    Frontiers in Molecular Biosciences, 2021
  • Circulating tumor cells as a tool to untangle the breast cancer heterogeneity issue
    Tania Rossi, Giulia Gallerani, Giovanni Martinelli, Roberta Maltoni, Francesco Fabbri
    Biomedicines, 2021
  • Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient
    Tania Rossi, Michela Palleschi, Davide Angeli, Michela Tebaldi, Giovanni Martinelli, et al.
    Frontiers in Medicine, 2021
  • Single-cell NGS-based analysis of copy number alterations reveals new insights in circulating tumor cells persistence in early-stage breast cancer
    Tania Rossi, Giulia Gallerani, Davide Angeli, Claudia Cocchi, Erika Bandini, et al.
    Cancers, 2020
  • Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report
    Roberta Maltoni, Michela Palleschi, Giulia Gallerani, Sara Bravaccini, Lorenzo Cecconetto, et al.
    Medicine United States, 2020
  • Adipocytes and micrornas crosstalk: A key tile in the mosaic of breast cancer microenvironment
    Erika Bandini, Tania Rossi, Giulia Gallerani, Francesco Fabbri
    Cancers, 2019
  • Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies
    Alberto Visioli, Fabrizio Giani, Nadia Trivieri, Riccardo Pracella, Elide Miccinilli, et al.
    Ebiomedicine, 2019
  • Crowdfunding for cancer research: the TRACe campaign as an example
    Giulia Gallerani, Pietro Fici, Alessandro Coatti, Paolo Mariotti, Francesca Passeri, et al.
    Lancet Oncology, 2019
  • Characterization of tumor cells using a medical wire for capturing circulating tumor cells: A 3D approach based on immunofluorescence and DNA FISH
    Giulia Gallerani, Claudia Cocchi, Martine Bocchini, Filippo Piccinini, Francesco Fabbri
    Journal of Visualized Experiments, 2017
  • DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: Correlation with clinical pathological factors and response to chemotherapy
    Silvia Carloni, Giulia Gallerani, Anna Tesei, Emanuela Scarpi, Giorgio Maria Verdecchia, et al.
    Oncotargets and Therapy, 2017
  • Circulating tumor cells: Back to the future
    Giulia Gallerani, Pietro Fici, Francesco Fabbri
    Frontiers in Oncology, 2017
  • Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer
    Pietro Fici, Giulia Gallerani, Anne-Pierre Morel, Laura Mercatali, Toni Ibrahim, et al.
    Oncotarget, 2017
  • Circulating tumor cells in the adenocarcinoma of the esophagus
    Giulia Gallerani, Francesco Fabbri
    International Journal of Molecular Sciences, 2016
  • CTCs in early breast cancer: A path worth taking
    Roberta Maltoni, Giulia Gallerani, Pietro Fici, Andrea Rocca, Francesco Fabbri
    Cancer Letters, 2016
  • Circulating tumor cells in early breast cancer: A connection with vascular invasion
    Roberta Maltoni, Pietro Fici, Dino Amadori, Giulia Gallerani, Claudia Cocchi, et al.
    Cancer Letters, 2015

RECENT SCHOLAR PUBLICATIONS

  • Horizontal transfer of functional extrachromosomal DNA via extracellular vesicles in FGFR2-amplified cancer
    I Salamon, G Gallerani, J Luebeck, G Storci, S Spandau, B Fontana, ...
    Cancer Research 86 (7_Supplement), 3345-3345 , 2026
    2026
  • P2. 06.81 Circulating Tumour Cells, Spread Through Air Space and Lymph-Nodal Micrometastasis in Surgically Resected Early-Stage NSCLC
    P Bertoglio, G Gallerani, F Ambrosi, F Bianchi, J Brandolini, N Nannini, ...
    Journal of Thoracic Oncology 20 (10), S329 , 2025
    2025
  • Abstract P3-01-17: Transcriptomic and phenotypic profiling of circulating tumor cells from metastatic breast cancer patients
    M Palleschi, T Rossi, S Bandini, M Zanoni, M Cortesi, E Bandini, A Rocca, ...
    Clinical Cancer Research 31 (12_Supplement), P3-01-17-P3-01-17 , 2025
    2025
  • Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity
    T Rossi, S Bandini, M Zanoni, M Cortesi, M Palleschi, E Bandini, A Rocca, ...
    Experimental hematology & oncology 14 (1), 67 , 2025
    2025
    Citations: 4
  • Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation
    T Rossi, M Valgiusti, M Puccetti, G Miserocchi, M Zanoni, D Angeli, ...
    Cell Death & Disease 16 (1), 223 , 2025
    2025
    Citations: 9
  • Extracellular vesicles deliver functional extrachromosomal DNA in FGFR2-amplified cancer of unknown primary
    I Salamon, G Gallerani, G Storci, B Fontana, S Seravalle, F Valle, ...
    2025
    Citations: 1
  • Vaccine-based immunotherapy for oropharyngeal and nasopharyngeal cancers
    DM Filippini, E Broseghini, C Liberale, G Gallerani, G Siepe, E Nobili, ...
    Journal of Clinical Medicine 14 (4), 1170 , 2025
    2025
    Citations: 9
  • Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
    A Cavazzoni, I Salamon, C Fumarola, G Gallerani, N Laprovitera, ...
    Molecular Therapy 32 (10), 3650-3668 , 2024
    2024
    Citations: 4
  • Extrachromosomal FGFR2 is delivered in extracellular vesicles in two models of cancer of unknown primary
    I Salamon, G Storci, B Fontana, S Serravalle, G Gallerani, R Roncarati, ...
    Cancer Research 84 (6_Supplement), 6957-6957 , 2024
    2024
  • Device and method for removing undesirable biological and/or chemical entities from biological fluids
    M Rigaud, Z Wainer, F Fabbri, G GALLERANI, F Pietro
    US Patent 11,596,728 , 2023
    2023
  • ARID1A in cancer: Friend or foe?
    B Fontana, G Gallerani, I Salamon, I Pace, R Roncarati, M Ferracin
    Frontiers in oncology 13, 1136248 , 2023
    2023
    Citations: 64
  • Settling the uncertainty about unconventional circulating tumor cells: Epithelial-to-mesenchymal transition, cell fusion and trogocytosis
    G Gallerani, T Rossi, M Ferracin, M Bonafè
    International Review of Cell and Molecular Biology 381, 99-111 , 2023
    2023
    Citations: 9
  • From phenotypical investigation to RNA-sequencing for gene expression analysis: A workflow for single and pooled rare cells
    T Rossi, D Angeli, G Martinelli, F Fabbri, G Gallerani
    Frontiers in Genetics 13, 1012191 , 2022
    2022
    Citations: 5
  • Dissecting molecular heterogeneity of circulating tumor cells (CTCs) from metastatic breast cancer patients through copy number aberration (CNA) and single nucleotide variant …
    T Rossi, D Angeli, M Tebaldi, P Fici, E Rossi, A Rocca, M Palleschi, ...
    Cancers 14 (16), 3925 , 2022
    2022
    Citations: 15
  • Case report: analysis of plasma extracellular vesicles in a triple negative spindle-cell metaplastic breast cancer patient
    I Vannini, M Urbini, M Melloni, T Rossi, G Gallerani, M Palleschi, I Azzali, ...
    Frontiers in medicine 9, 827206 , 2022
    2022
    Citations: 1
  • CNA profiling of single CTCs in locally advanced esophageal cancer patients during therapy highlights unexplored molecular pathways
    G Gallerani, T Rossi, M Valgiusti, D Angeli, P Fici, S De Fanti, E Bandini, ...
    Cancers 13 (24), 6369 , 2021
    2021
    Citations: 8
  • Early detection and investigation of extracellular vesicles biomarkers in breast cancer
    E Bandini, T Rossi, E Scarpi, G Gallerani, I Vannini, S Salvi, I Azzali, ...
    Frontiers in molecular biosciences 8, 732900 , 2021
    2021
    Citations: 17
  • Circulating tumor cells as a tool to untangle the breast cancer heterogeneity issue
    T Rossi, G Gallerani, G Martinelli, R Maltoni, F Fabbri
    Biomedicines 9 (9), 1242 , 2021
    2021
    Citations: 15
  • Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models
    N Laprovitera, C Fumarola, E Porcellini, S Cairo, G Gallerani, ...
    Cancer Research 81 (13_Supplement), 3011-3011 , 2021
    2021
  • Case report: analysis of circulating tumor cells in a triple negative spindle-cell metaplastic breast cancer patient
    T Rossi, M Palleschi, D Angeli, M Tebaldi, G Martinelli, I Vannini, ...
    Frontiers in medicine 8, 689895 , 2021
    2021
    Citations: 6

MOST CITED SCHOLAR PUBLICATIONS

  • Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs
    F Fabbri, S Carloni, W Zoli, P Ulivi, G Gallerani, P Fici, E Chiadini, ...
    Cancer letters 335 (1), 225-231 , 2013
    2013
    Citations: 261
  • Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations
    G Barriere, P Fici, G Gallerani, F Fabbri, W Zoli, M Rigaud
    Annals of translational medicine 2 (11), 109 , 2014
    2014
    Citations: 207
  • Epithelial mesenchymal transition: a double-edged sword
    G Barriere, P Fici, G Gallerani, F Fabbri, M Rigaud
    Clinical and translational medicine 4 (1), 14 , 2015
    2015
    Citations: 197
  • ARID1A in cancer: Friend or foe?
    B Fontana, G Gallerani, I Salamon, I Pace, R Roncarati, M Ferracin
    Frontiers in oncology 13, 1136248 , 2023
    2023
    Citations: 64
  • Circulating tumor cells in early breast cancer: A connection with vascular invasion
    R Maltoni, P Fici, D Amadori, G Gallerani, C Cocchi, M Zoli, A Rocca, ...
    Cancer letters 367 (1), 43-48 , 2015
    2015
    Citations: 48
  • CTCs in early breast cancer: A path worth taking
    R Maltoni, G Gallerani, P Fici, A Rocca, F Fabbri
    Cancer letters 376 (2), 205-210 , 2016
    2016
    Citations: 40
  • Single-cell NGS-based analysis of copy number alterations reveals new insights in circulating tumor cells persistence in early-stage breast cancer
    T Rossi, G Gallerani, D Angeli, C Cocchi, E Bandini, P Fici, M Gaudio, ...
    Cancers 12 (9), 2490 , 2020
    2020
    Citations: 39
  • Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer
    P Fici, G Gallerani, AP Morel, L Mercatali, T Ibrahim, E Scarpi, D Amadori, ...
    Oncotarget 8 (2), 2423 , 2016
    2016
    Citations: 39
  • Adipocytes and microRNAs crosstalk: a key tile in the mosaic of breast cancer microenvironment
    E Bandini, T Rossi, G Gallerani, F Fabbri
    Cancers 11 (10), 1451 , 2019
    2019
    Citations: 26
  • Circulating tumor cells in the adenocarcinoma of the esophagus
    G Gallerani, F Fabbri
    International Journal of Molecular Sciences 17 (8), 1266 , 2016
    2016
    Citations: 22
  • Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies
    A Visioli, F Giani, N Trivieri, R Pracella, E Miccinilli, MG Cariglia, ...
    EBioMedicine 44, 346-360 , 2019
    2019
    Citations: 20
  • Early detection and investigation of extracellular vesicles biomarkers in breast cancer
    E Bandini, T Rossi, E Scarpi, G Gallerani, I Vannini, S Salvi, I Azzali, ...
    Frontiers in molecular biosciences 8, 732900 , 2021
    2021
    Citations: 17
  • Dissecting molecular heterogeneity of circulating tumor cells (CTCs) from metastatic breast cancer patients through copy number aberration (CNA) and single nucleotide variant …
    T Rossi, D Angeli, M Tebaldi, P Fici, E Rossi, A Rocca, M Palleschi, ...
    Cancers 14 (16), 3925 , 2022
    2022
    Citations: 15
  • Circulating tumor cells as a tool to untangle the breast cancer heterogeneity issue
    T Rossi, G Gallerani, G Martinelli, R Maltoni, F Fabbri
    Biomedicines 9 (9), 1242 , 2021
    2021
    Citations: 15
  • Characterization of tumor cells using a medical wire for capturing circulating tumor cells: a 3D approach based on immunofluorescence and DNA FISH
    G Gallerani, C Cocchi, M Bocchini, F Piccinini, F Fabbri
    Journal of Visualized Experiments: Jove, 56936 , 2017
    2017
    Citations: 12
  • Circulating tumor cells: Back to the future
    G Gallerani, P Fici, F Fabbri
    Frontiers in Oncology 6, 275 , 2017
    2017
    Citations: 10
  • Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation
    T Rossi, M Valgiusti, M Puccetti, G Miserocchi, M Zanoni, D Angeli, ...
    Cell Death & Disease 16 (1), 223 , 2025
    2025
    Citations: 9
  • Vaccine-based immunotherapy for oropharyngeal and nasopharyngeal cancers
    DM Filippini, E Broseghini, C Liberale, G Gallerani, G Siepe, E Nobili, ...
    Journal of Clinical Medicine 14 (4), 1170 , 2025
    2025
    Citations: 9
  • Settling the uncertainty about unconventional circulating tumor cells: Epithelial-to-mesenchymal transition, cell fusion and trogocytosis
    G Gallerani, T Rossi, M Ferracin, M Bonafè
    International Review of Cell and Molecular Biology 381, 99-111 , 2023
    2023
    Citations: 9
  • CNA profiling of single CTCs in locally advanced esophageal cancer patients during therapy highlights unexplored molecular pathways
    G Gallerani, T Rossi, M Valgiusti, D Angeli, P Fici, S De Fanti, E Bandini, ...
    Cancers 13 (24), 6369 , 2021
    2021
    Citations: 8